PBM
HELP

Propel Bio Management’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Propel Bio Management’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,368
Closed -$230K – 22
2024
Q2 		$230K Hold
22,368
– – 0.15% 22
2024
Q1 		$351K Hold
22,368
– – 0.2% 26
2023
Q4 		$349K Buy
+22,368
New +$416K 0.29% 30

Other funds holding HELP

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.73B AUM 24.11% 1-Year Est. Return

Propel Bio Management's HELP Position: Q3 2024 in Review

Propel Bio Management sold out of Helus Pharma Inc. Common Stock (HELP) in Q3 2024, closing a stake of 22,368 shares — an estimated $230K sold.

Propel Bio Management first reported a position in HELP in Q4 2023 and held it in 3 quarters. The position peaked at $351K in Q1 2024. 46 funds tracked by Wall St. Rank hold HELP as of Q3 2024.

  • Propel Bio Management reported no remaining Helus Pharma Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Propel Bio Management sold 22,368 Helus Pharma Inc. Common Stock shares in Q3 2024, an estimated $230K.
  • Propel Bio Management first reported a position in Helus Pharma Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Propel Bio Management's Helus Pharma Inc. Common Stock position peaked at $351K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q3 2024.

Based on Propel Bio Management's 13F filing for Q3 2024, filed 13 Nov 2024.